Terms: = Gastric cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
23 results:
1. Crohn's disease-associated ATG16L1 T300A genotype is associated with improved survival in gastric cancer.
Ma C; Storer CE; Chandran U; LaFramboise WA; Petrosko P; Frank M; Hartman DJ; Pantanowitz L; Haritunians T; Head RD; Liu TC
EBioMedicine; 2021 May; 67():103347. PubMed ID: 33906066
[TBL] [Abstract] [Full Text] [Related]
2. O-glycans truncation modulates gastric cancer cell signaling and transcription leading to a more aggressive phenotype.
Freitas D; Campos D; Gomes J; Pinto F; Macedo JA; Matos R; Mereiter S; Pinto MT; Polónia A; Gartner F; Magalhães A; Reis CA
EBioMedicine; 2019 Feb; 40():349-362. PubMed ID: 30662000
[TBL] [Abstract] [Full Text] [Related]
3. Sym015: A Highly Efficacious Antibody Mixture against
Poulsen TT; Grandal MM; Skartved NJØ; Hald R; Alifrangis L; Koefoed K; Lindsted T; Fröhlich C; Pollmann SE; Eriksen KW; Dahlman A; Jacobsen HJ; Bouquin T; Pedersen MW; Horak ID; Lantto J; Kragh M
Clin Cancer Res; 2017 Oct; 23(19):5923-5935. PubMed ID: 28679766
[No Abstract] [Full Text] [Related]
4. MiR-16 mediates trastuzumab and lapatinib response in erbb-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L; Cordo Russo RI; Rivas MA; Mercogliano MF; Izzo F; Oakley RH; Pereyra MG; De Martino M; Proietti CJ; Yankilevich P; Roa JC; Guzmán P; Cortese E; Allemand DH; Huang TH; Charreau EH; Cidlowski JA; Schillaci R; Elizalde PV
Oncogene; 2016 Dec; 35(48):6189-6202. PubMed ID: 27157613
[TBL] [Abstract] [Full Text] [Related]
5. Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion.
Shimura T; Yoshida M; Fukuda S; Ebi M; Hirata Y; Mizoshita T; Tanida S; Kataoka H; Kamiya T; Higashiyama S; Joh T
BMC Cancer; 2012 May; 12():205. PubMed ID: 22646534
[TBL] [Abstract] [Full Text] [Related]
6. Nuclear translocation of pro-amphiregulin induces chemoresistance in gastric cancer.
Yoshida M; Shimura T; Fukuda S; Mizoshita T; Tanida S; Kataoka H; Kamiya T; Nakazawa T; Higashiyama S; Joh T
Cancer Sci; 2012 Apr; 103(4):708-15. PubMed ID: 22320154
[TBL] [Abstract] [Full Text] [Related]
7. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract] [Full Text] [Related]
8. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Luber B; Deplazes J; Keller G; Walch A; Rauser S; Eichmann M; Langer R; Höfler H; Hegewisch-Becker S; Folprecht G; Wöll E; Decker T; Endlicher E; Lorenzen S; Fend F; Peschel C; Lordick F
BMC Cancer; 2011 Dec; 11():509. PubMed ID: 22152101
[TBL] [Abstract] [Full Text] [Related]
9. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Wainberg ZA; Lin LS; DiCarlo B; Dao KM; Patel R; Park DJ; Wang HJ; Elashoff R; Ryba N; Hecht JR
Br J Cancer; 2011 Sep; 105(6):760-5. PubMed ID: 21811258
[TBL] [Abstract] [Full Text] [Related]
10. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.
Iqbal S; Goldman B; Fenoglio-Preiser CM; Lenz HJ; Zhang W; Danenberg KD; Shibata SI; Blanke CD
Ann Oncol; 2011 Dec; 22(12):2610-2615. PubMed ID: 21415234
[TBL] [Abstract] [Full Text] [Related]
11. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
[TBL] [Abstract] [Full Text] [Related]
12. Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.
Kim HK; Choi IJ; Kim CG; Kim HS; Oshima A; Yamada Y; Arao T; Nishio K; Michalowski A; Green JE
Pharmacogenomics J; 2012 Apr; 12(2):119-27. PubMed ID: 21173787
[TBL] [Abstract] [Full Text] [Related]
13. Population-based differences in treatment outcome following anticancer drug therapies.
Ma BB; Hui EP; Mok TS
Lancet Oncol; 2010 Jan; 11(1):75-84. PubMed ID: 20129130
[TBL] [Abstract] [Full Text] [Related]
14. Mucinous gastric carcinomas: clinicopathologic and molecular analyses.
Choi JS; Kim MA; Lee HE; Lee HS; Kim WH
Cancer; 2009 Aug; 115(15):3581-90. PubMed ID: 19479974
[TBL] [Abstract] [Full Text] [Related]
15. gastric cancer in the era of molecularly targeted agents: current drug development strategies.
Arkenau HT
J Cancer Res Clin Oncol; 2009 Jul; 135(7):855-66. PubMed ID: 19363621
[TBL] [Abstract] [Full Text] [Related]
16. Epidermal growth factor receptor (egfr) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery.
Galizia G; Lieto E; Orditura M; Castellano P; Mura AL; Imperatore V; Pinto M; Zamboli A; De Vita F; Ferraraccio F
World J Surg; 2007 Jul; 31(7):1458-68. PubMed ID: 17516110
[TBL] [Abstract] [Full Text] [Related]
17. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Dragovich T; McCoy S; Fenoglio-Preiser CM; Wang J; Benedetti JK; Baker AF; Hackett CB; Urba SG; Zaner KS; Blanke CD; Abbruzzese JL
J Clin Oncol; 2006 Oct; 24(30):4922-7. PubMed ID: 17050876
[TBL] [Abstract] [Full Text] [Related]
18. Lysophospholipids transactivate HER2/neu (erbb-2) in human gastric cancer cells.
Shida D; Kitayama J; Yamaguchi H; Yamashita H; Mori K; Watanabe T; Nagawa H
Biochem Biophys Res Commun; 2005 Feb; 327(3):907-14. PubMed ID: 15649431
[TBL] [Abstract] [Full Text] [Related]
19. Absence of evidence for HER2 amplification in nasopharyngeal carcinoma.
Yan J; Fang Y; Huang BJ; Liang QW; Wu QL; Zeng YX
Cancer Genet Cytogenet; 2002 Jan; 132(2):116-9. PubMed ID: 11850071
[TBL] [Abstract] [Full Text] [Related]
20. [Correlation of DNA ploidy, c-erB-2 protein tissue status, level of PCNA expression and clinical outcome in gastric carcinomas].
Takamura H; Yonemura Y; Fonseca L; Ninomiya I; Tsugawa K; Miwa K; Miyazaki I
Nihon Geka Gakkai Zasshi; 1995 Apr; 96(4):213-22. PubMed ID: 7753016
[TBL] [Abstract] [Full Text] [Related]
[Next]
